{"id":59538,"date":"2024-06-16T10:04:26","date_gmt":"2024-06-16T08:04:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/electra-therapeutics-presents-late-breaking-clinical-data-at-eha2024-from-ongoing-phase-1b-study-of-ela026-in-secondary-hemophagocytic-lymphohistiocytosis-shlh\/"},"modified":"2024-06-16T10:04:26","modified_gmt":"2024-06-16T08:04:26","slug":"electra-therapeutics-presents-late-breaking-clinical-data-at-eha2024-from-ongoing-phase-1b-study-of-ela026-in-secondary-hemophagocytic-lymphohistiocytosis-shlh","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/electra-therapeutics-presents-late-breaking-clinical-data-at-eha2024-from-ongoing-phase-1b-study-of-ela026-in-secondary-hemophagocytic-lymphohistiocytosis-shlh\/","title":{"rendered":"Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)"},"content":{"rendered":"
\n

\nELA026 demonstrated a high overall response rate (ORR) across a range of sHLH patients <\/i>and a favorable safety profile in this life-threatening hyperinflammatory condition<\/i><\/p>\n

\nIn patients with the poorest prognosis, those with malignancy-associated HLH, <\/i>early treatment with ELA026 resulted in 100% ORR and improved survival<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Electra Therapeutics, Inc.<\/b><\/a>, a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of clinical data for ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition. The results were presented today as one of six abstracts selected for oral presentation in a late-breaking session at the European Hematology Association (EHA) Congress in Madrid, Spain.<\/p>\n

<\/a>
<\/a><\/p>\n

\nResults were reported for sHLH patients in the ongoing Phase 1b clinical study, which has enrolled a majority of patients with the deadliest sHLH subtype, malignancy-associated HLH (mHLH). In treatment\u2011naive mHLH patients, ELA026 achieved a 100% overall response rate (ORR) by week 4 and improved survival at two months compared to natural history studies. ELA026 also demonstrated a high response rate across a range of sHLH patients and a favorable safety profile in this patient population.<\/p>\n

\nELA026 is a first-in-class monoclonal antibody that targets signal regulatory protein (SIRP)-\u03b1\/\u03b21\/\u03b3 on the cell surface of myeloid cells and T lymphocytes, the pathological immune cells that induce hyperinflammation in sHLH. The Phase 1b study is an ongoing open-label, multi-dose, single-arm, multicenter study designed to evaluate the safety and efficacy of ELA026, assess biomarkers, and identify a dose for Phase 2\/3 testing (ClinicalTrials.gov identifier: NCT05416307<\/b><\/a>).<\/p>\n

\n\u201cThese data show very promising results for ELA026 as a potential treatment for sHLH, which is a challenging disease that is devastating for patients and has no approved treatment options,\u201d said Swaminathan P. Iyer, MD, Professor in the Department of Lymphoma\/Myeloma at The University of Texas MD Anderson Cancer Center. \u201cNotably, the analysis reveals improved survival was achieved with ELA026 in treatment-na\u00efve mHLH patients, suggesting benefit from early treatment intervention for patients with this rapidly progressing disease.\u201d<\/p>\n

\nStudy Results Presented at EHA 2024 Congress<\/b><\/p>\n

\nThe oral presentation at EHA2024, entitled \u201cELA026 Targeting of SIRP(+) Immune Cells Results in a High Response Rate and Improved 2-Month Survival of Treatment-na\u00efve Malignancy-associated Hemophagocytic Lymphohistiocytosis in a Phase 1 Study,\u201d was presented by the lead author, Abhishek Maiti, MD, Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. The data describe analysis of sHLH patients in three cohorts of the ongoing Phase 1b clinical study, including the following highlights:<\/p>\n